Literature DB >> 12614325

Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.

Christian E Gross1, Paula Ravenscroft, Sandra Dovero, Mohamed Jaber, Bernard Bioulac, Erwan Bezard.   

Abstract

While levodopa-induced neurochemical changes have been studied in animal models of Parkinson's disease, very little is known regarding the effects of levodopa administration in normal animals. The present study investigates the effects normal and MPTP-lesioned mice chronically treated with two different doses of levodopa. We assess changes in striatal dopamine (DA) receptor binding, striatal DA receptor mRNA levels and striatal neuropeptide precursor levels (preproenkephalin-A [PPE-A]; preprotachykinin [PPT]; preproenkephalin-B [PPE-B]). The extent of the lesion was measured by striatal DA transporter binding and stereological estimation of the number of tyrosine hydroxylase immunoreactive neurones in the substantia nigra pars compacta (SNc). In non-lesioned animals, chronic levodopa treatment induced an increase in PPE-A mRNA, whereas both D3R binding and PPE-B mRNA levels were dramatically increased in the lesioned animals in a dose dependent manner. The present results show that chronic levodopa administration may induce pathophysiological changes, even in the absence of a lesion of the nigro-striatal pathway, suggesting that the sensitization process involves predominantly the indirect striatofugal pathway in non-lesioned animals, whereas the direct pathway is primarily involved in lesioned animals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614325     DOI: 10.1046/j.1471-4159.2003.01600.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Altered pallido-pallidal synaptic transmission leads to aberrant firing of globus pallidus neurons in a rat model of Parkinson's disease.

Authors:  Cristina Miguelez; Stéphanie Morin; Audrey Martinez; Michel Goillandeau; Erwan Bezard; Bernard Bioulac; Jérôme Baufreton
Journal:  J Physiol       Date:  2012-08-13       Impact factor: 5.182

2.  Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease.

Authors:  Samantha R Cote; Eldo V Kuzhikandathil
Journal:  Neurosci Lett       Date:  2014-11-20       Impact factor: 3.046

3.  Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.

Authors:  Anna Nilsson; Maria Fälth; Xiaoqun Zhang; Kim Kultima; Karl Sköld; Per Svenningsson; Per E Andrén
Journal:  Mol Cell Proteomics       Date:  2009-01-08       Impact factor: 5.911

4.  Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Authors:  Ludovico Arcuri; Riccardo Viaro; Simone Bido; Francesco Longo; Mariangela Calcagno; Pierre-Olivier Fernagut; Nurulain T Zaveri; Girolamo Calò; Erwan Bezard; Michele Morari
Journal:  Neurobiol Dis       Date:  2016-01-22       Impact factor: 5.996

Review 5.  Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

Authors:  Wassilios Meissner; Caroline Prunier; Denis Guilloteau; Sylvie Chalon; Christian E Gross; Erwan Bezard
Journal:  Mol Neurobiol       Date:  2003-12       Impact factor: 5.590

Review 6.  Opioid system in L-DOPA-induced dyskinesia.

Authors:  Jing Pan; Huaibin Cai
Journal:  Transl Neurodegener       Date:  2017-01-17       Impact factor: 8.014

Review 7.  Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.

Authors:  Abdeslam Chagraoui; Giuseppe Di Giovanni; Philippe De Deurwaerdère
Journal:  Biomolecules       Date:  2022-02-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.